Kaitlyn Pritchard

Engaging government with respect to the importance of the Canada/US/Mexico Free Trade Agreement (CUSMA) to the life sciences sector & ensuring open supply chains to trade partners and tariff-free access to medical devices. Engaging with the Office of the Minister of Indigenous Services, Office of the Minister of Finance, Office of the Minister of Health, and Members of Parliament regarding the public reimbursement of Abbott brand products and Abbott's rapid diagnostic systems. Working with Food, Health & Consumer Products (FHCP) Infant Formula Council on the proposed regulatory modernization of Food & Drug Regulations Divisions 24 & 25.

Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada Annual federal Budgets and Budget updates relating to the biopharmaceutical industry. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.

C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program. The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines. Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry. Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry. Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention. Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.

strategic policy objectives for the MedTech sector regarding 2026 CUSMA review. export permits and export controls • Government investments in Artificial Intelligence (AI) compute infrastructure; • Government policy considerations on health data trust and privacy. Substances addressed in the third phase of the Chemicals Management Plan. Support from ISED, with respect to Strategic Innovation Fund Medical device cost recovery schemes with respect to filing fees Engage in pre-market and post-market regulatory requirements to ensure efficient and predictable processes that supports safety, effectiveness, quality, and Canada’s competitiveness in the medical device sector. Amendments to Copyright Act, regarding Technology Protection Measures (TPMs)

NATIONAL ZERO-EMISSIONS VEHICLE STRATEGY: Communicating with government officials about the National Zero-Emissions Vehicle Strategy, more specifically (i) providing expert industry input on the strategy, (ii) participating in various advisory groups and (iii) participating in the government review and any future activities related to this topic. These communications will involve discussions about design, infrastructure, incentives, supply, and public awareness. NEW MARKET ENTRANTS: Communicating with government officials about new market entrants into Canada, including ensuring there is a level playing field with automakers regarding the sale and assembly of vehicles in Canada. INTERNATIONAL TRADE: Communicating with government officials about international trade, trade issues and support measures related to the automotive industry and automotive manufacturing, including potential tariffs on automobiles, automotive parts and batteries. GHG REGULATIONS: Communicating with government officials about greenhouse gas regulations and any related consultations with respect to the current or future Canadian standards. COMPETITIVENESS AND ECONOMIC & TRADE UNCERTAINTY: Communicating with government officials about potential support, policies and programs, including but not limited to the Auto Strategy and its pillars, Employment Insurance (EI), preventing labour disruptions (and to re-train employees) and maintain manufacturing competitiveness given the current economic and trade uncertainty. STRATEGIC RESPONSE FUND (SRF) AND STRATEGIC INNOVATION FUND ("SIF"): Communicating with government officials about funding under the Strategic Innovation Fund and the newly created Strategic Response Fund, to ensure and maintain the competitiveness of automobile manufacturing in Canada. REGIONAL ECONOMIC DEVELOPMENT - Communicating with government officials about regional economic development programs and funding, including those offered by the Federal Economic Development Agency. BANK ACT: Communicating with the Government of Canada about the statutory review of the Bank Act, SC 1991, c. 46, more specifically about vehicle leasing. VEHICLE THEFT: Communicating with government officials about vehicle thefts across Canada, including measures to limit vehicle theft. The goal of these communications is, in part, to ensure cross-departmental coordination in addressing the issue. TRAVEL DOCUMENTS: Communicating with government officials about the processing of travel documents, more specifically visas. MOTOR VEHICLE SAFETY ACT: Communicating with government officials about the Motor Vehicle Safety Act, more specifically (i) alignment with American safety standards, (ii) flexibility on regulations for vehicles, (iii) target setting for greenhouse gas emissions and (iv) improved recall completion rates. MEASURES AGAINST FORCED AND CHILD LABOUR: Communicating with government officials about measures to eliminate forced and child labour, more specifically (i) monitoring legislative and regulatory developments to increase supply chain transparency and (ii) ensuring industry has enough time to comply with future supply chain transparency obligations. LUXURY TAX: Communicating with government officials about luxury taxes, more specifically (i) ensuring luxury taxes are removed from electric vehicles ("EVs"), (ii) ensuring luxury taxes are removed (or reduced) on recreational boats and (iii) ensuring luxury taxes do not conflict with other government measures, including reductions in greenhouse gas emissions. INVESTMENT TAX INCENTIVES: Communicating with government officials about investment tax incentives under the Income Tax Act, including the Investment Tax Credit ("ITC"). INTERNATIONAL STUDENT WORK: Communicating with government officials about international students, more specifically eligibility for off-campus work during studies at a designated learning institutions (“DLIs”). ELECTRIC VEHICHLE ("EV") INFRASTRUCTURE: Communicating with government officia

Communicate with government on behalf of members, regarding the impact of changes to Canada-US Trade agreements, as they apply to medical technologies. Following Royal Assent of Bill C-244, An Act to Amend the Copyright Act (diagnosis, maintenance and repair), monitor development of a right to repair framework and its potential impact on the medical device industry. Communicate with government potential regulatory measures to protect patient safety as a consequence of Bill C-244 and future policies and/org legislation regarding right to repair. Establishment of a Diabetes Fund for medical devices associated with diabetes management. Monitor and participate in discussions to advance and support digital health and data. Medical Device Regulations (SOR/98-282) that require compliance by the medical device technology industry. Addressing issues and providing advice related to Medical Device Regulations in Canada Development of policies that will improve the market in Canada for innovative medical technologies. C-244 An Act to amend the Copyright Act (Diagnosis, Maintenance and Repair Gain information on the potential impacts for the medical device industry and given any patient safety concerns, seek relevant amendments.

Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes. Discussion focused on sharing perspectives on priorities and resourcing. In particular, a shared observation of an increase in submission reviews exceeding established timeframes and increasing challenges with securing pre-filing meetings were discussed Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP). World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG). US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products. The government's Science and Technology strategy as it relates to the biopharmaceutical industry. Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations. Smart Regulations as it relates to the biopharmaceutical industry. Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits. Policies and programs as it relates to vaccine approval, procurement and public awareness of immunization. Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services. Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting. Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products. Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive. Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products. Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products. Partnership opportunities as it relates to Canada's policy and programs to improve health in the developing world, such as Maternal and Child Health. New Substances Notification Regulations as it relates to the biopharmaceutical industry. National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework. Income Tax Act as it relates to biopharmaceutical products. Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharm

Discussions on North American trade. The development of a Canadian Manufacturing Strategy, as it relates to the competitiveness of Canada’s automotive manufacturing industry. Strategic Innovation Fund and Innovation Supercluster Initiative, as it relates to the competitiveness of Canada’s automotive manufacturing industry. Infrastructure Development, as it relates to the development of electric and alternative fueling and manufacturing infrastructure (specifically hydrogen). Federal tax policy, as it relates to the competitiveness of Canada's automotive manufacturing industry.

Seeking to liberalize air policy and bilateral air transportation agreements. Seeking to change border facilitation processes and policies. Seeking to amend security screening policies, regulations and resourcing. Seeking to amend proposed changes to airport policies. Advocate for the development of Sustainable Aviation Fuel (SAF) in Canada. Collaboration to support efforts to strengthen workforce development for continued economic growth and resilience. Collaboration to support efforts to diversify market opportunities through air connectivity. Seeking to enable opportunities for future infrastructure development. Seeking to amend existing airport lease agreements. Seeking to enable technology and innovative solutions to maximize efficiency and safe movement of goods and people. Seeking to amend and expand electronic travel authorization programs. Seeking to amend aviation policies and regulations to protect the current and future viability and accessibility of an airport. Canadian Aviation Regulations (CARs), associated standards, Advisory Circulas and Notice of Proposed Amendments with respect to Aerodromes, Airports and Heliports.